



CONTENTS

GLOBAL NEWS

- Increasing Capital Expenditures seen with bio/pharmaceutical companies
- GMP inspections of APIs: Japan joins international collaboration
- New guidelines developed for HER2 testing for gastroesophageal adenocarcinoma
- US FDA clears backlog of nearly 4000 excipient formulations in its Inactive Ingredient Database

PHARMA INDIA

- Indian Medical Association collates list of irrational and unsafe combination drugs
- Vietnam banned 39 Indian pharmaceutical firms
- Indian pharma companies to see 30% growth rate in 2017

REGULATORY ROUNDUP

- ICH to revamp GCP guidelines
- Q&A Guidance recommendations on electronic informed consent
- FDA anesthesia/sedation drug warning for young children and pregnant women

MERGERS /ACQUISITIONS /COLLABORATIONS

- Allergan to expand CNS- R&D pipeline with acquisition of Chase pharmaceuticals
- QuintilesIMS acquired TKL Research's clinical trials division
- Novartis acquired Selexys pharmaceuticals to broaden hematology pipeline
- AstraZeneca enters into collaboration with Bicycle Therapeutics

DRUGS: APPROVALS & LAUNCHES

- US FDA approves Sanofi's Soliqua 100/33
- US FDA approves new indication for empagliflozin
- US FDA approves Novo Nordisk's Xultophy® 100/3.6 to treat type 2 diabetes
- The innovative 6-in-1 paediatric vaccine launched in India

DRUGS: DEVELOPMENT & CLINICAL TRIALS

GLOBAL NEWS

1. Increasing Capital Expenditures seen with bio/pharmaceutical companies

Bio/pharmaceutical companies have increased their annual Capital Expenditure (CapEx) by 6.8% (\$35.3 billion) from 2010 to 2015, while the overall revenue growth of the bio/pharmaceutical industry has been just 3.3% during the same period.



The major factor that impedes quicker growth of the contract manufacturing and development industry is captive capacity; and employment of capital towards development of new plant and equipment by bio/pharmaceutical companies is an important factor that indicate the industry's approach towards the make or buy decision.

In the past 5 years, bio/pharma companies have invested about \$150 billion for new plant and facilities, as reported by Bio/Pharma CapEx Trends 2016, which was 10 times more than the investment done by CMOs for themselves.

[Source: health.economicstimes.indiatimes.com](http://health.economicstimes.indiatimes.com)

- Baricitinib demonstrated significant improvement in rheumatoid arthritis patients
- Pfizer's Xeljanz shows positive Phase 3 results in psoriatic arthritis
- Positive top line results with Pfizer's investigational compound PF-05280014
- Tagrisso found to be superior over chemotherapy in NSCLC

PATENTS: NEW APPROVALS /LITIGATIONS /SETTLEMENTS

- Pfizer wins 2 process patents for etanercept
- India denies patent to prostate cancer drug Xtandi

TECHNOLOGY/ NDDS NEWS

- Modified PEG as a new drug delivery technology
- Web-based computational tool for cancer treatment optimization

Contact Us:

Dr. Tausif Monif

President - Global Operations
Tausifmonif@lambda-cro.com

Dr. Mrinal Kammili

Ex. Director – Global Head, BD
mrinal@lambda-cro.com

Disclaimer: "The information compiled and published in this newsletter have been collected from various public domain resources available on web and relevant magazines. The Public Domain information is not confidential and may be freely distributed and copied. However, transmission or reproduction of protected items beyond that allowed by fair use as defined in the copyright laws requires the written permission of the copyright owners, if any. Lambda directly or indirectly shall not be responsible for any legal/ethical litigation claimed by any professional agency / bodies."